Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial
Authors' conclusion
Treat-to-target ULT in gout is accompanied by HRQoL improvements evident by 24 weeks and sustained through 72 weeks. HRQoL gains with treat-to-target ULT are most prominent in the domains of physical function, mobility, and pain and are greatest in those with lower baseline levels of inflammation and comorbidity.
Study context
- Population
- Participants with gout receiving protocolized treat-to-target urate-lowering therapy (ULT) in a 72-week randomised trial (98.9% male; mean age 62.4 years)
- Participants
- 878 participants
- Primary endpoint
- Change in HRQoL (Veterans RAND-12 Item Health Survey and EQ-5D-3L)
- Follow-up
- 72 weeks
Methodological detailspost hoc analysis, pooled allopurinol and febuxostat arms
- Post hoc analysis
- Pooled allopurinol and febuxostat arms
Primary result
As reported in the abstract
HRQoL change over follow-up
- Health-related quality of life (HRQoL) scores overall, particularly physical function, mobility and pain domains, improved significantly over 72 weeks, with improvements noted by 24 weeks
- P < 0.001
Further findings
Factors associated with poorer baseline HRQoL
- Younger age, non-White race, tophi (for EQ-5D-3L), higher serum urate level and greater comorbidity
- Multivariable linear regression
Baseline factors associated with HRQoL improvement over 72 weeks
- Lower CRP level and lower comorbidity scores
- Similar changes by ULT assignment
- General estimating equations
Original publication
Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial. Arthritis Care Res (Hoboken). Published 17 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →